Literature DB >> 35802496

Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs.

Franziska R Traube1, Marcel Stern2, Annika J Tölke1, Martina Rudelius3, Ernesto Mejías-Pérez2, Nada Raddaoui1, Beate M Kümmerer4,5, Céline Douat6, Filipp Streshnev1, Manuel Albanese2, Paul R Wratil2, Yasmin V Gärtner1, Milda Nainytė1, Grazia Giorgio7, Stylianos Michalakis7, Sabine Schneider1, Hendrik Streeck4, Markus Müller1, Oliver T Keppler2, Thomas Carell1.   

Abstract

The emergence of more transmissible or aggressive variants of SARS-CoV-2 requires the development of antiviral medication that is quickly adjustable to evolving viral escape mutations. Here we report the synthesis of chemically stabilized small interfering RNA (siRNA) against SARS-CoV-2. The siRNA can be further modified with receptor ligands such as peptides using CuI -catalysed click-chemistry. We demonstrate that optimized siRNAs can reduce viral loads and virus-induced cytotoxicity by up to five orders of magnitude in cell lines challenged with SARS-CoV-2. Furthermore, we show that an ACE2-binding peptide-conjugated siRNA is able to reduce virus replication and virus-induced apoptosis in 3D mucociliary lung microtissues. The adjustment of the siRNA sequence allows a rapid adaptation of their antiviral activity against different variants of concern. The ability to conjugate the siRNA via click-chemistry to receptor ligands facilitates the construction of targeted siRNAs for a flexible antiviral defence strategy.
© 2022 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH.

Entities:  

Keywords:  Corona pandemic; SARS-CoV-2; antiviral compounds; peptide RNA conjugates; siRNA

Mesh:

Substances:

Year:  2022        PMID: 35802496      PMCID: PMC9350007          DOI: 10.1002/anie.202204556

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   16.823


  31 in total

1.  RNA interference is mediated by 21- and 22-nucleotide RNAs.

Authors:  S M Elbashir; W Lendeckel; T Tuschl
Journal:  Genes Dev       Date:  2001-01-15       Impact factor: 11.361

2.  Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.

Authors:  Manisha Balwani; Eliane Sardh; Paolo Ventura; Paula Aguilera Peiró; David C Rees; Ulrich Stölzel; D Montgomery Bissell; Herbert L Bonkovsky; Jerzy Windyga; Karl E Anderson; Charles Parker; Samuel M Silver; Siobán B Keel; Jiaan-Der Wang; Penelope E Stein; Pauline Harper; Daphne Vassiliou; Bruce Wang; John Phillips; Aneta Ivanova; Janneke G Langendonk; Raili Kauppinen; Elisabeth Minder; Yutaka Horie; Craig Penz; Jihong Chen; Shangbin Liu; John J Ko; Marianne T Sweetser; Pushkal Garg; Akshay Vaishnaw; Jae B Kim; Amy R Simon; Laurent Gouya
Journal:  N Engl J Med       Date:  2020-06-11       Impact factor: 91.245

3.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

4.  Click-modified anandamide siRNA enables delivery and gene silencing in neuronal and immune cells.

Authors:  Julian Willibald; Johannes Harder; Konstantin Sparrer; Karl-Klaus Conzelmann; Thomas Carell
Journal:  J Am Chem Soc       Date:  2012-07-23       Impact factor: 15.419

5.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque.

Authors:  Bao-jian Li; Qingquan Tang; Du Cheng; Chuan Qin; Frank Y Xie; Qiang Wei; Jun Xu; Yijia Liu; Bo-jian Zheng; Martin C Woodle; Nanshan Zhong; Patrick Y Lu
Journal:  Nat Med       Date:  2005-08-21       Impact factor: 53.440

6.  An interactive website tracking COVID-19 vaccine development.

Authors:  Madhumita Shrotri; Tui Swinnen; Beate Kampmann; Edward P K Parker
Journal:  Lancet Glob Health       Date:  2021-03-02       Impact factor: 26.763

Review 7.  Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.

Authors:  Lei Zhao; Song Li; Wu Zhong
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

8.  Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs.

Authors:  Franziska R Traube; Marcel Stern; Annika J Tölke; Martina Rudelius; Ernesto Mejías-Pérez; Nada Raddaoui; Beate M Kümmerer; Céline Douat; Filipp Streshnev; Manuel Albanese; Paul R Wratil; Yasmin V Gärtner; Milda Nainytė; Grazia Giorgio; Stylianos Michalakis; Sabine Schneider; Hendrik Streeck; Markus Müller; Oliver T Keppler; Thomas Carell
Journal:  Angew Chem Int Ed Engl       Date:  2022-08-12       Impact factor: 16.823

Review 9.  SARS-CoV-2 variants, spike mutations and immune escape.

Authors:  William T Harvey; Alessandro M Carabelli; Ben Jackson; Ravindra K Gupta; Emma C Thomson; Ewan M Harrison; Catherine Ludden; Richard Reeve; Andrew Rambaut; Sharon J Peacock; David L Robertson
Journal:  Nat Rev Microbiol       Date:  2021-06-01       Impact factor: 78.297

Review 10.  Coronavirus biology and replication: implications for SARS-CoV-2.

Authors:  Philip V'kovski; Annika Kratzel; Silvio Steiner; Hanspeter Stalder; Volker Thiel
Journal:  Nat Rev Microbiol       Date:  2020-10-28       Impact factor: 60.633

View more
  1 in total

1.  Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs.

Authors:  Franziska R Traube; Marcel Stern; Annika J Tölke; Martina Rudelius; Ernesto Mejías-Pérez; Nada Raddaoui; Beate M Kümmerer; Céline Douat; Filipp Streshnev; Manuel Albanese; Paul R Wratil; Yasmin V Gärtner; Milda Nainytė; Grazia Giorgio; Stylianos Michalakis; Sabine Schneider; Hendrik Streeck; Markus Müller; Oliver T Keppler; Thomas Carell
Journal:  Angew Chem Int Ed Engl       Date:  2022-08-12       Impact factor: 16.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.